Loss on drying:
Solubility in water:
C6 H12 O6
White to off-white fine-crystalline powder
ca. 230 ºC
Stable under normal processing and storage conditions of foods and dietary supplements, no indications for undesired reactions or interactions with other food constituyents or ingredients of dietary supplements
The spice saffron is obtained from picking the bright red or orange ends of the saffron flower pistils, also know as stigmas. It is both a spice and a herb with strong properties in pharmaceutics, cosmetics, perfumery, and textile dye-producing industries. Although it contains both alpha and beta-carotene, two potent natural antioxidants and colouring agents, saffron owes most of its bright red pigment to a particular carotenoid called alpha-crocin. According to several studies, the crocins in saffron protect nerve cells from free radicals damage and promote nerve generation.
DCI is found in several plants and fruits, in buckwheat, but also carob and certain melons.
caromax saffron as an appetite regulator effect
One of the most noticeable effects is its ability to reduce hunger associated with anxiety and subsequently maximize natural satiety, thus reducing the amount of food eaten. This property helps control food intake and weight control.
caromax saffron as a high anti-depressant effect
Depression is a severe disorder in today’s society, with estimates of lifetime prevalence as high as 21% of the general population in some developed countries, at the study ” Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial” patients were randomly assigned to receive a capsule of saffron 30 mg[sol ]day (BD) (Group 1) or a capsule of placebo (BD) (Group 2) for a 6-week study. At six weeks, Crocus sativus produced a significantly better outcome on the Hamilton depression rating scale than the placebo. The results of this study indicate the efficacy of Crocus sativus in the treatment of mild to moderate depression
DCI and polycystic ovary syndrome (PCOS)
Insulin resistance plays a crucial role in the pathophysiology of PCOS. A deficiency in a specific d-chiro-inositol-containing inositolphosphoglycan mediator may contribute to insulin resistance in women with PCOS. Study results indicate that the use of insulin-sensitizing agents in patients with PCOS may improve their sensitivity to the effects of insulin on glucose and lipid metabolism but also ameliorate clinical and biochemical manifestations. In one study, women suffering from PCOS given 600 mg/d for 6 – 8 weeks in comparison to a placebo group DCI improved glucose tolerance, decreased serum androgens and improved ovulation. Insulin-sensitising therapy seems, therefore, a promising therapy for the treatment of PCOS, offering metabolic and gynaecologic benefits for women who suffer from this syndrome. Should favourable results with DCI be repeated, it could play a role in such therapies.
D-chiroinositol and fat metabolism and storage
Abnormal lipid profiles often accompany diabetes. While DCI alone may already reduce elevated lipid levels, combination with other lipid-reducing agents, may be beneficial.
Humans well tolerate DCI. Long-term DCI ingestion by humans from different plant foods which contain DCI like buckwheat or carob pods has not shown adverse effects. Neither has a higher incidence of negative effects compared to placebo groups been reported from human studies with DCI of several hundred mg per person per day for several weeks. Based on the historical evidence, it can reasonably be concluded that the intake of a reasonable amount of DCI is safe.
a food and not as a food additive. Whenever specific pharmaceutical effects are claimed, products with DCI may be classified as a pharmaceutical and require a respective authorisation.
In the EU, DCI has been consumed as part of the regular diet by consumption of carob and soy products for decades if not centuries. Only consumption of well-exceeding levels the intake from these sources may require an examination of whether the specific use has to be authorised. Health claims have to be approved by the EU under conditions outlined in Regulation 1924/2006/EC, especially art. 13 and 14. Claims going beyond a health claim require the authorisation of DCI formulations as a pharmaceutical.
In Japan, DCI-containing products would be qualified by FOSHU (Foods for Specified Health Uses) responsible for the approval provided that the general requirements of effectiveness, safety, appropriate ingredients and adequate quality control are met.
In the USA, DCI is qualified for use in dietary supplements. Any claims on DCI functions have to be based on scientific evidence and to be accompanied by the following statement: “The Food and Drug Administration has not evaluated this statement. This product is not intended to diagnose, treat, cure, or prevent any disease”. Any claim referring to treatment or cure of a disease makes a product a pharmaceutical which would require authorisation under pharmaceuticals legislation.
Euronutra is prepared to assist its customers in obtaining the necessary authorisations for their products.
Leaflet PDF about saffromax